Clinical Trial Update: Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update for dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)
• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED | Results posted: 2017-10-16